Divi's Laboratories Limited (DIVISLAB) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Divi's Laboratories enters the Q1 FY27 results season with a strong tailwind from a weaker rupee and the structural demand shifts driven by the US Biosecure Act. Investors will be focused on whether these external factors can help the company achieve its double-digit revenue growth guidance while maintaining stable EBITDA margins amid persistent generic API pricing pressure.

Divi's Laboratories Limited Q1 Results Date and Time

The board is scheduled to meet on August 01, 2026, to approve the Q1 FY27 unaudited financial results.

The earnings call is scheduled for August 01, 2026, at 14:00 IST.

What to expect from Divi's Laboratories Limited's Q1 FY27 results

Divi's is targeting double-digit revenue growth for FY27, supported by the ongoing ramp-up of custom synthesis projects and a favourable export environment. The company's unhedged exposure to the USD/INR, which traded at ~96.57 in late July 2026, provides a mechanical revenue tailwind compared to the Q1 FY26 average of ~85.5–86.0. While management has maintained a stable EBITDA margin guidance of 32–32.5%, the core operating margin will be tested by raw material costs, which remained at 42.0% of revenue in Q4 FY26. The upcoming call will likely clarify the progress of three dedicated custom synthesis projects and whether the long-standing generic API pricing pressure has finally shown signs of stabilization.

Key Things To Watch

Performance vs Guidance Tracking: Tracking progress against management's stated FY27 targets.

• Group revenue growth — Double-digit (≥10% YoY) — Target for FY27
• Group EBITDA margin — Stable (~32–32.5% level) — Open-ended for FY27

Dedicated capex project updates: Status of the three large custom synthesis projects backed by long-term supply agreements.

• Revenue recognition tied to customer validation and regulatory approvals, with a typical 2-year cycle from capex deployment
• Capital work in progress stood at Rs. 2,113 Cr as of March 31, 2026, requiring conversion to revenue-generating assets

Operating metric trajectory: Key trends in the API and custom synthesis segments.

• Custom synthesis mix reached 55–57% by Q3/Q4 FY26, trending upwards
• Generic API pricing pressure has persisted for 6+ quarters with no clear inflection point observed yet
• Capacity utilization remained consistent at ~80% throughout FY26

Risks and headwinds to monitor: External factors impacting margins and supply chain stability.

• Raw material inflation remains a risk, with spot-market business in South America and Asia exposed to pricing volatility
• Logistics disruptions in West Asia caused higher freight rates in Q4 FY26, though production was unaffected
• Regulatory inspection outcomes for Kakinada and peptide facilities are expected within 1–2 years